dpp-4 inhibitors and glp-1 agonists Glucagon-like peptide-1 GLP 1 Receptor Agonists and
Description
Most people taking GLP-1s do not develop new or worsening eye problems
Follow-up appointments are required to receive refills
The pills seem to cause similar side effects to injections without causing as much weight loss, Moore said
The region is becoming more accessible due to better medical infrastructure and the increasing adoption of GLP-1s in chronic disease programmes
Encouragingly, GLP1R/GIPR agonists have demonstrated favorable outcomes in T2DM when studied in human clinical trials
however, to our knowledge, no larger clinical trials with GLP-1 RAs in HFrEF are ongoing
